Octave Bioscience Partners with Quest Diagnostics to Expand Access to Multiple Sclerosis Disease Activity Test Nationwide
ByAinvest
Tuesday, Dec 2, 2025 1:56 am ET1min read
DGX--
Octave Bioscience has formed a strategic collaboration with Quest Diagnostics to expand patient access to the Octave Multiple Sclerosis Disease Activity Test across the US. The test is a clinically and analytically validated multi-analyte blood test that provides reliable, objective data to support treatment decisions. It measures 18 validated protein biomarkers, giving a clear view of disease activity. The test is reimbursed by multiple payers and supported by a patient affordability program.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet